RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
-13.65%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.62B
AUM Growth
-$585M
(-18%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
5.7%
Top 10 Holdings %
Top 10 Hldgs %
51.83%
Holding
74
New
4
Increased
19
Reduced
26
Closed
3
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$86.5M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$59.5M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$49.6M |
| 4 |
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
|
+$24.8M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$23.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$41.9M |
| 2 |
UnitedHealth
UNH
|
+$27.3M |
| 3 |
LivaNova
LIVN
|
+$24.6M |
| 4 |
ICU Medical
ICUI
|
+$21.6M |
| 5 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.46% |
| 2 | Consumer Staples | 2.55% |
| 3 | Industrials | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Bioventus
BVS
$922M
| $8.91M | 0.34% |
1,306,339
+9,600
| +0.7% | +$98K |
2021 Q1
5 quarters
|
|
52
Starling Oncology
STLN
$663M
| $8.79M | 0.34% |
1,736,116
-678,316
| -28% | -$4.94M |
2021 Q4
2 quarters
|
|
53
DELISTED
LAVA Therapeutics
LVTX
| $8.05M | 0.31% |
2,816,196
| – | – |
2021 Q1
5 quarters
|
|
54
DELISTED
Allakos
ALLK
| $7.97M | 0.3% |
2,545,275
-14,700
| -0.6% | -$54.9K |
2018 Q3
15 quarters
|
|
55
DELISTED
HOOKIPA Pharma
HOOK
| $7.44M | 0.28% |
456,225
-7,440
| -2% | -$123K |
2019 Q2
12 quarters
|
|
56
Invivyd
IVVD
$179M
| $6.3M | 0.24% |
1,920,960
| – | – |
2021 Q3
3 quarters
|
|
57
ALX Oncology
ALXO
$124M
| $6.2M | 0.24% |
766,797
-5,600
| -0.7% | -$61K |
2020 Q3
7 quarters
|
|
58
Privia Health
PRVA
$2.77B
| $6M | 0.23% |
+206,113
| New | +$5.24M |
2022 Q2
0 quarters
|
|
59
Alpha Teknova
TKNO
$418M
| $4.77M | 0.18% |
567,800
| – | – |
2021 Q2
4 quarters
|
|
|
ACHL
60
DELISTED
Achilles Therapeutics
ACHL
| $4.05M | 0.15% |
1,608,089
| – | – |
2021 Q1
5 quarters
|
|
61
Immatics
IMTX
$1.07B
| $3.92M | 0.15% |
449,661
-275,339
| -38% | -$2.18M |
2020 Q3
7 quarters
|
|
62
Neurogene
NGNE
$444M
| $3.54M | 0.14% |
171,847
-1,425
| -0.8% | -$34.8K |
2019 Q4
10 quarters
|
|
63
Kalaris Therapeutics
KLRS
$50.7M
| $3.21M | 0.12% |
35,799
| – | – |
2020 Q3
7 quarters
|
|
|
TCRR
64
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.17M | 0.12% |
1,094,645
| – | – |
2019 Q1
13 quarters
|
|
65
Stereotaxis
STXS
$105M
| $2.74M | 0.1% |
1,487,495
| – | – |
2019 Q3
11 quarters
|
|
66
Xeris Biopharma Holdings
XERS
$1.78B
| $1.61M | 0.06% |
1,046,587
| – | – |
2018 Q2
16 quarters
|
|
|
BCEL
67
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $1.43M | 0.05% |
800,306
| – | – |
2019 Q2
12 quarters
|
|
|
SONX
68
DELISTED
Sonendo, Inc.
SONX
| $857K | 0.03% |
498,131
| – | – |
2021 Q4
2 quarters
|
|
69
Cabaletta Bio
CABA
$275M
| $738K | 0.03% |
696,377
| – | – |
2019 Q4
10 quarters
|
|
70
Cytosorbents Corp
CTSO
$9.74M
| $583K | 0.02% |
13,318
| – | – |
2020 Q3
7 quarters
|
|
|
AYLA
71
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $372K | 0.01% |
341,030
-108,701
| -24% | -$248K |
2020 Q2
8 quarters
|
|
|
72
ICU Medical
ICUI
$4.07B
| – | – |
-96,869
| Closed | -$21.6M | – |
|
|
73
UnitedHealth
UNH
$355B
| – | – |
-53,445
| Closed | -$27.3M | – |
|
|
EPZM
74
DELISTED
Epizyme, Inc
EPZM
| – | – |
-454,475
| Closed | -$523K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q2 2022 Portfolio in Review
As of Q2 2022, Redmile Group held 74 positions worth $2.62B, down 18% from $3.2B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Redmile Group deployed $149M of net new capital in Q2 2022, opening 4 new positions and adding to 19 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 913,319 shares worth $72.8M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Industrials.
On the sell side, the largest reduction was argenx, an estimated $41.9M trimmed.
- Redmile Group's largest Q2 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 913,319 shares worth $72.8M.
- Redmile Group added most to Seagen Inc. Common Stock in Q2 2022, an estimated $59.5M increase.
- Redmile Group's biggest Q2 2022 reduction was argenx, cutting an estimated $41.9M.
- Redmile Group fully exited UnitedHealth in Q2 2022, selling an estimated $27.3M.
- Redmile Group's ten largest holdings make up 52% of its $2.62B portfolio in Q2 2022.
- Redmile Group opened 4 new positions and closed 3 in Q2 2022.
- Redmile Group's portfolio value fell 18% quarter-over-quarter to $2.62B.
Based on Redmile Group's 13F filing for Q2 2022, filed 15 Aug 2022.